文献速递妇科产科

盆腔炎性疾病与卵巢癌风险:更新版荟萃分析

Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis.
PubMed 文献 · Gynecol Oncol · 2020-02-07

结果显示盆腔炎性疾病(PID)与卵巢癌风险升高相关(HR 1.18,95%CI 1.13-1.22;I2=41%),各亚组中关联均显著。

要点

  • PID与卵巢癌风险升高相关(HR 1.18,95%CI 1.13-1.22)
  • 亚洲患者、病例对照研究、侵袭性、交界性及非浆液性卵巢癌亚组关联均显著
  • 需未来大型设计良好的研究验证该关联

核心结论

  • PID与卵巢癌风险升高相关(HR 1.18,95%CI 1.13-1.22;I2=41%)。

主要发现

  • PID与卵巢癌风险升高相关(HR 1.18,95%CI 1.13-1.22;I2=41%)。
  • 亚洲患者中PID与卵巢癌关联HR 1.25(95%CI 1.10-1.42),异质性I2=0%-38%。
  • 病例对照研究中关联HR 1.15(95%CI 1.08-1.23)。
  • 侵袭性卵巢癌HR 1.25(95%CI 1.20-1.30),交界性卵巢癌HR 1.28(95%CI 1.19-1.37)。
  • 非浆液性卵巢癌HR 1.15(95%CI 1.07-1.24)。

关键数值与推荐

  • PID与卵巢癌风险升高相关(HR 1.18,95%CI 1.13-1.22;I2=41%)。
  • 亚洲患者亚组HR 1.25(95%CI 1.10-1.42)。
  • 侵袭性卵巢癌亚组HR 1.25(95%CI 1.20-1.30)。
  • 交界性卵巢癌亚组HR 1.28(95%CI 1.19-1.37)。
  • 非浆液性卵巢癌亚组HR 1.15(95%CI 1.07-1.24)。

临床怎么用

  • 对盆腔炎性疾病患者应关注卵巢癌风险,但需结合个体情况评估。

局限性

  • 需未来大型、设计良好的研究 corroborate 本研究发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Because of conflicting reports regarding the relationship between pelvic inflammatory disease (PID) and ovarian cancer, we performed an updated meta-analysis to investigate the association between PID and the risk of this malignancy. METHODS: Embase, PubMed, and Web of Science were searched up until November 1, 2019. Hazard ratios (HRs), along with 95% confidence intervals (CIs), were calculated to analyse outcomes. RESULTS: We included 16 studies in this meta-analysis. PID was associated with an increased risk of ovarian cancer (HR 1.18, 95% CI 1.13 to 1.22; I2 = 41%). In subgroup analyses according to ethnicity, study design, tumour invasiveness, and type of ovarian cancer, PID was significantly associated with ovarian cancer in all subgroups. The lowest heterogeneity (I2 = 0% to 38%) was observed for associations between PID and ovarian cancer in Asian patients (HR 1.25, 95% CI 1.10 to 1.42), ovarian cancer in case-control studies (HR 1.15, 95% CI 1.08 to 1.23), invasive ovarian cancer (HR 1.25, 95% CI 1.20 to 1.30), borderline ovarian cancer (HR 1.28, 95% CI 1.19 to 1.37), and non-serous ovarian cancer (HR 1.15, 95% CI 1.07 to 1.24). CONCLUSIONS: This updated meta-analysis demonstrated that PID is associated with an increased risk of ovarian cancer. Future large, well-designed studies are necessary to corroborate our findings.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Piao J, Lee EJ, Lee M, et al. Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis. Gynecol Oncol. 2020. PMID: 32037193. doi:10.1016/j.ygyno.2020.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。